TrialClinical and translational science2020

Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations.

Yuichiro Takeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.